CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 711 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper May 21, 2019 Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy... March 31, 2020 How Your Primary Care Provider Can Help You Throughout Your Cancer... March 5, 2021 Load more HOT NEWS As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... Research with integrity – the importance of communication EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... Alcohol linked to more than 740,000 new cancer cases globally in...
